Table 1 Patients characteristics according to type of chemotherapy added to trastuzumab
Docetaxel (106) | Vinorelbine (72) | P | |
|---|---|---|---|
Median Age, years (range) | 55 (33-73) | 54 (29-81) | 0.47 |
HER2 Status | 0.05 | ||
IHC 3+ | 86 (81%) | 66 (92%) | |
IHC 2+1 | 20 (19%) | 6 (8%) | |
ER positive2 | 50 (47%) | 32 (44%) | 0.63 |
PgR positive3 | 34 (32%) | 22 (31%) | 0.64 |
Initial disease Stage4 | < 0.01 | ||
I | 12 (11%) | 7 (10%) | |
II and III | 71 (67%) | 58 (80%) | |
IV | 23 (22%) | 6 (8%) | |
Prior adjuvant/neoadjuvant chemotherapy | 70 (66%) | 55 (76%) | 0.14 |
Prior exposure to anthracycline5 | 62 (58%) | 50 (69%) | 0.14 |
Prior exposure to taxanes5 | 16 (15%) | 31 (43%) | < 0.01 |
Prior endocrine therapy6 | 43 (40%) | 35 (49%) | 0.24 |
Median DFS in months (range)7 | 21 (0-136) | 24 (0-146) | 0.33 |
Sites of metastatic disease | |||
Liver | 58 (55%) | 33 (46%) | 0.24 |
Lung | 43 (41%) | 18 (25%) | 0.03 |
Bone | 46 (43%) | 30 (42%) | 0.82 |
Soft-tissue/nodes | 71 (67%) | 37 (51%) | 0.04 |
Central nervous system | 4 (4%) | 3 (4%) | 0.90 |
Visceral involvement (lung + liver + CNS) | 82 (77%) | 47 (65%) | 0.08 |
Number metastatic sites | 0.09 | ||
1 | 31 (29%) | 28 (39%) | |
2 | 30 (28%) | 25 (35%) | |
≥ 3 | 45 (42%) | 19 (26%) |